Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer

被引：0
|
作者：
Shuxia Qin
Lidan Yi
Sini Li
Chongqing Tan
Xiaohui Zeng
Liting Wang
Ye Peng
Xiaomin Wan
机构：
[1] Central South University,Department of Pharmacy, The Second Xiangya Hospital
[2] Central South University,Xiangya Nursing School
[3] Central South University,PET
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Atezolizumab; Bladder cancer; Cost-effectiveness; Markov model; Urothelial carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3399 / 3408
页数：9
相关论文
共 50 条
  • [31] Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.
    Lista, Alfonso Gomez De Liano
    Romero-Laorden, Nuria
    Gajate, Pablo
    Orta-Ruiz, Alberto
    Jimenez, Jesus Garcia-Donas
    Miranda, Maria Jose
    Estevez, Sergio Vazquez
    Molins, Carmen
    Pernaut, Cristina
    Cordero, Marta Gonzalez
    Fernandez, Ovidio
    Sanchez, Jose Garcia
    Maeso, Iria Gonzalez
    Blazquez, Patricia Rodriguez
    Reig, Oscar
    Maroto-Rey, Pablo
    Martin, Almudena
    Ramirez, Ignacio
    Puente, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [32] First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis
    Wan, XiaoMin
    Luo, Xia
    Tan, ChongQing
    Zeng, XiaoHui
    Zhang, YuCong
    Peng, LiuBao
    CANCER, 2019, 125 (20) : 3526 - 3534
  • [33] Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer
    Barufaldi, Laura A.
    de Albuquerque, Rita de C. R.
    do Nascimento, Aline
    Martins, Luis Felipe L.
    Zimmermann, Ivan R.
    de Souza, Mirian C.
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 33 - 40
  • [34] Cost-effectiveness of atezolizumab plus chemotherapy for advanced/ recurrent endometrial cancer
    Huo, Gengwei
    Song, Ying
    Chen, Peng
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (05)
  • [35] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    JAMA NETWORK OPEN, 2021, 4 (02)
  • [36] Cost-effectiveness of Paclitaxel plus Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan
    Saito, Shota
    Muneoka, Yusuke
    Ishikawa, Takashi
    Akazawa, Kouhei
    CLINICAL THERAPEUTICS, 2017, 39 (12) : 2380 - 2388
  • [37] Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States
    Criss, Steven D.
    Mooradian, Meghan J.
    Watson, Tina R.
    Gainor, Justin F.
    Reynolds, Kerry L.
    Kong, Chung Yin
    JAMA NETWORK OPEN, 2019, 2 (09)
  • [38] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Athanasopoulos, C.
    Haiderali, A.
    Huang, M.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2022, 25 (12) : S184 - S184
  • [39] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [40] Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China
    Shang, Fangjian
    Zhang, Boyuan
    Kang, Shuo
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (03) : 337 - 343
12345